NASDAQ:NUVA - NuVasive Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$61.50 +0.19 (+0.31 %)
(As of 11/20/2018 04:00 PM ET)
Previous Close$61.31
Today's Range$60.25 - $61.89
52-Week Range$44.62 - $72.41
Volume563,400 shs
Average Volume733,678 shs
Market Capitalization$3.17 billion
P/E Ratio32.20
Dividend YieldN/A
Beta0.78
NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.

Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:NUVA
Previous Symbol
CUSIP67070410
Phone858-909-1800

Debt

Debt-to-Equity Ratio0.74
Current Ratio3.45
Quick Ratio1.83

Price-To-Earnings

Trailing P/E Ratio32.20
Forward P/E Ratio28.21
P/E Growth1.84

Sales & Book Value

Annual Sales$1.03 billion
Price / Sales3.07
Cash Flow$4.7344 per share
Price / Cash12.99
Book Value$15.68 per share
Price / Book3.92

Profitability

EPS (Most Recent Fiscal Year)$1.91
Net Income$83 million
Net Margins2.24%
Return on Equity13.87%
Return on Assets6.55%

Miscellaneous

Employees2,600
Outstanding Shares51,420,000
Market Cap$3.17 billion
OptionableOptionable

NuVasive (NASDAQ:NUVA) Frequently Asked Questions

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

How will NuVasive's stock buyback program work?

NuVasive declared that its board has authorized a share buyback plan on Wednesday, October 25th 2017, which authorizes the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's leadership believes its shares are undervalued.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) released its quarterly earnings data on Tuesday, October, 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.62 by $0.06. The medical device company had revenue of $271.30 million for the quarter, compared to analyst estimates of $265.70 million. NuVasive had a return on equity of 13.87% and a net margin of 2.24%. The company's revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.52 earnings per share. View NuVasive's Earnings History.

When is NuVasive's next earnings date?

NuVasive is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for NuVasive.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive updated its FY18 earnings guidance on Tuesday, October, 30th. The company provided earnings per share (EPS) guidance of $2.15-2.23 for the period, compared to the Thomson Reuters consensus estimate of $2.38. The company issued revenue guidance of $1.105-1.110 billion, compared to the consensus revenue estimate of $1.10 billion.

What price target have analysts set for NUVA?

15 brokers have issued 1 year price objectives for NuVasive's shares. Their predictions range from $47.00 to $82.00. On average, they anticipate NuVasive's share price to reach $68.4286 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price. View Analyst Price Targets for NuVasive.

What is the consensus analysts' recommendation for NuVasive?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NuVasive.

What are Wall Street analysts saying about NuVasive stock?

Here are some recent quotes from research analysts about NuVasive stock:
  • 1. According to Zacks Investment Research, "NuVasive’s third-quarter revenue exceeded the consensus mark. However, earnings fell short of the mark. Operating profit contracted significantly on escalating costs and expenses. Full-year outlook also seems disappointing which fails to indicate any sign of rebound in the near term. Headwinds like pricing pressure, reimbursement issues and competitive landscape are the major downsides. Notably, in the quarter under review, pricing pressure remained stable at a negative 2%, below the industry average. NuVasive has underperformed its industry over the past three months. On a positive note, NuVasive delivered balanced growth in both of its business wings. Also, a solid show by the international business buoys optimism. The company expects to see strong demand for new products and positive surgeon conversion efforts. Moreover, contributions from the company’s the recently-completed consolidation of SafePassage was significant." (11/14/2018)
  • 2. Needham & Company LLC analysts commented, "NUVA’s 3Q18 revenue beat while its EPS missed. Management raised revenue guidance but lowered EPS guidance. Organic growth increased to 8% in 3Q18 from 5% in 2Q18 as improved domestic growth offset slower international growth. Operating margin was 220 bps below consensus as management decided to exploit an improving spine market by reinvesting in SG&A (up 70 bps Y/Y) and R&D (up 50 bps Y/Y). Gross margin met consensus and West Carrollton remains on track to deliver 130-150 bps of margin benefit in 2019. While the margin performance is frustrating, we expect the stronger growth combined with in-sourcing to drive better margin performance in 2019 and reiterate our Buy rating." (10/31/2018)
  • 3. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month PT of $58 on shares of NUVA. NUVA has faced a growing number of challenges over the past 18 months, particularly in its US business which has pressured the stock. We think it is appropriate to remain on the sidelines, until we gain more confidence in the reacceleration of US growth and OM improvement. $58 price target is based on an 11x EV/EBITDA multiple on our 2019 EBITDA estimate." (10/19/2018)

Has NuVasive been receiving favorable news coverage?

News headlines about NUVA stock have trended somewhat positive on Tuesday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. NuVasive earned a news impact score of 1.9 on InfoTrie's scale. They also gave headlines about the medical device company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the stock's share price in the next several days.

Who are some of NuVasive's key competitors?

Who are NuVasive's key executives?

NuVasive's management team includes the folowing people:
  • Mr. Gregory T. Lucier, Chairman & CEO (Age 54)
  • Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 51)
  • Mr. Matthew W. Link, Exec. VP of Strategy, Technology & Corp. Devel. (Age 43)
  • Dr. Peter M. Leddy, Exec. VP of People & Culture (Age 55)
  • Mr. Harry Skip Kiil, Exec. VP of Global Commercial (Age 43)

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (3.26%), Eagle Asset Management Inc. (2.71%), Dimensional Fund Advisors LP (2.48%), Fisher Asset Management LLC (2.45%), Victory Capital Management Inc. (1.95%) and Anchor Capital Advisors LLC (1.94%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Lesley H Howe, Matthew Link and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.

Which institutional investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Janus Henderson Group PLC, Massachusetts Financial Services Co. MA, Vaughan Nelson Investment Management L.P., Teachers Advisors LLC, Fort Washington Investment Advisors Inc. OH, DNB Asset Management AS and AXA. View Insider Buying and Selling for NuVasive.

Which institutional investors are buying NuVasive stock?

NUVA stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Redmile Group LLC, Investment Counselors of Maryland LLC, Glenmede Trust Co. NA, PointState Capital LP, Macquarie Group Ltd., Eagle Asset Management Inc. and Crown Advisors Management Inc.. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $61.50.

How big of a company is NuVasive?

NuVasive has a market capitalization of $3.17 billion and generates $1.03 billion in revenue each year. The medical device company earns $83 million in net income (profit) each year or $1.91 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.

What is NuVasive's official website?

The official website for NuVasive is http://www.nuvasive.com.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]


MarketBeat Community Rating for NuVasive (NASDAQ NUVA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  651 (Vote Outperform)
Underperform Votes:  532 (Vote Underperform)
Total Votes:  1,183
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share (EPS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel